Holen Sie sich die Stockscreener-App
0.2927
0.10%
-0.0003
Handel nachbörslich:
.28
-0.0127
-4.34%
Schlusskurs vom Vortag:
$0.293
Offen:
$0.285
24-Stunden-Volumen:
885.99K
Relative Volume:
2.40
Marktkapitalisierung:
$12.09M
Einnahmen:
$7.10M
Nettoeinkommen (Verlust:
$-39.43M
KGV:
-0.3114
EPS:
-0.94
Netto-Cashflow:
$-46.50M
1W Leistung:
-7.81%
1M Leistung:
-17.78%
6M Leistung:
-33.48%
1J Leistung:
-64.47%
1-Tages-Spanne:
$0.2626
$0.2966
1-Wochen-Bereich:
$0.26
$0.3179
52-Wochen-Spanne:
$0.26
$0.87
Spruce Biosciences Inc Stock (SPRB) Company Profile
Firmenname
Spruce Biosciences Inc
Sektor
Branche
Telefon
(415) 655-4168
Adresse
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Vergleichen Sie SPRB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
0.2927 | 12.09M | 7.10M | -39.43M | -46.50M | -0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-11 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-03-14 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-03-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | Eingeleitet | Guggenheim | Buy |
| 2021-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | The Benchmark Company | Speculative Buy |
| 2021-11-16 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-11-03 | Eingeleitet | Cowen | Outperform |
| 2020-11-03 | Eingeleitet | Credit Suisse | Outperform |
| 2020-11-03 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-11-03 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Spruce Biosciences Inc Aktie (SPRB) Neueste Nachrichten
Spruce Biosciences reports delayed annual filing By Investing.com - Investing.com South Africa
Spruce Biosciences reports delayed annual filing - Investing.com
Spruce Biosciences Delays Annual Report Filing - TipRanks
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Spruce Biosciences stock hits 52-week low at $0.32 - Investing.com
In-Depth Analysis Of The Global Congenital Adrenal Hyperplasia Market: Key Drivers, Trends, Growth Opportun... - WhaTech
SPRUCE BIOSCIENCES INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Analysts Set Spruce Biosciences, Inc. (NASDAQ:SPRB) PT at $2.38 - Defense World
SPRB Stock Touches 52-Week Low at $0.34 Amid Steep Decline - Investing.com India
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Spruce Biosciences (SPRB) to Release Quarterly Earnings on Wednesday - Defense World
Harbour Biomed newco HBM Alpha pens $395M hyperplasia drug deal - BioWorld Online
SPRB stock touches 52-week low at $0.34 amid sharp annual decline - Investing.com
Short Interest in Kingsoft Co. Limited (OTCMKTS:KSFTF) Increases By 79.4% - Defense World
Archer-Daniels-Midland Company (NYSE:ADM) Receives Consensus Rating of “Reduce” from Brokerages - Defense World
Traws Pharma, Inc. (NASDAQ:TRAW) Short Interest Update - Defense World
Spruce Biosciences, Inc. (NASDAQ:SPRB) Short Interest Up 81.4% in February - Defense World
SPRB stock touches 52-week low at $0.34 amid sharp annual decline By Investing.com - Investing.com South Africa
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Spruce Biosciences, Inc. (SPRB) Reports Q2 Loss, Tops Revenue Estimates - MSN
NeoGenomics (NEO) Tops Q4 Earnings Estimates - Yahoo Finance
The Prothena Corporation plc (PRTA) had a good session last reading, didn’t it? - US Post News
Element Solutions Inc (NYSE:ESI) Receives $30.14 Consensus Price Target from Analysts - Defense World
Alamos Gold Inc. (TSE:AGI) Receives C$28.78 Average Target Price from Brokerages - Defense World
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives $3.90 Consensus Target Price from Analysts - Defense World
Spruce Biosciences Inc [SPRB] Investment Appeal on the Rise - Knox Daily
Spruce Biosciences Inc (NASDAQ: SPRB) Stock Has Gained 4.05% Over The Month – Is There Room For Growth? - Marketing Sentinel
Should You Expect Akero Therapeutics Inc (NASDAQ:AKRO) To Recover From Its 70.02% Gain From Highs? - Marketing Sentinel
Five Point Holdings LLC (NYSE: FPH): Can The Stock Still Lose Despite An 54.23% YTD Gain? - Marketing Sentinel
Why you might not want to use AI to spruce up your job application - Yahoo
Spruce Biosciences Inc (SPRB) Stock Price and Analyst Predictions - The News Heater
Spruce Biosciences Inc (NASDAQ:SPRB) stock: You might be surprised - US Post News
Examining OppFi Inc (OPFI) stock is warranted - US Post News
(PDF) Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials - ResearchGate
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives $3.90 Consensus Target Price from Brokerages - Defense World
After A 1.47% Jump In The Last Week, Does Amprius Technologies Inc (NYSE: AMPX) Still Make Sense To Buy? - Marketing Sentinel
Finanzdaten der Spruce Biosciences Inc-Aktie (SPRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):